| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 10917976 | Radiotherapy and Oncology | 2015 | 6 Pages |
Abstract
We have shown that the MLD and the prescribed PTV dose could be accurately predicted for NSCLC patients. This method can guide the treatment planner to achieve optimal OAR sparing and tumour dose escalation.
Keywords
Related Topics
Life Sciences
Biochemistry, Genetics and Molecular Biology
Cancer Research
Authors
Steven F. Petit, Wouter van Elmpt,